Pfizer ($PFE) Withdraws Sickle Cell Drug Oxbryta from Global Markets

Sep 25, 2024, 09:07 PM

Pfizer Inc. ($PFE) announced on Wednesday that it is voluntarily withdrawing all lots of its sickle cell disease treatment Oxbryta (voxelotor) from worldwide markets. The decision comes after data indicated an imbalance in vaso-occlusive crises and fatal events associated with the drug. This withdrawal marks a significant setback for Pfizer, following its $5.4 billion acquisition of Global Blood Therapeutics, the original developer of Oxbryta. The company stated that the overall benefit of Oxbryta no longer outweighs the risks involved.